4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc Interim Clinical Data Presented at NACFC - Corporate Call Transcript

Nov 03, 2022 / 08:30PM GMT
Release Date Price: $8.89 (+7.76%)
Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to the 4D Molecular Therapeutics 4D-710 Phase I/II Interim Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded.

With that, I will hand the call over to August Moretti, Chief Financial Officer, who will make introductory comments.

August J. Moretti
4D Molecular Therapeutics, Inc. - CFO

Thank you, operator, and welcome, everyone, to 4D Molecular Therapeutics 4D-710 Phase I/II Interim Clinical Data Conference Call. With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; and Dr. Robert Fishman, our Chief Medical Officer and Pulmonology Therapeutic Area Head.

As a reminder, on this call, we will be making forward-looking statements regarding our clinical data from our 4D-710 Phase I/II clinical trial, product development plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot